Lapatinib Pharos

Lapatinib, the active ingredient in Lapatinib Pharos, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats HER2‑positive breast cancer, metastatic breast cancer and gastric cancer in adult patients.

GNH USA supplies Lapatinib Pharos as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Lapatinib is used to target HER2‑driven cancers, particularly in breast and gastric malignancies.

- HER2‑positive breast cancer: improves progression‑free survival when combined with chemotherapy. - Metastatic breast cancer: delays disease progression in patients whose tumours overexpress HER2. - Gastric cancer: used in HER2‑positive advanced gastric adenocarcinoma to extend survival.

Lapatinib may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Diarrhea: watery stools that may require antidiarrheal therapy. - Rash: maculopapular skin eruptions, often on the trunk. - Nausea: sensation of queasiness, sometimes with vomiting. - Fatigue: persistent tiredness affecting daily activities.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis requiring monitoring. - Cardiac dysfunction: decreased left‑ventricular ejection fraction or heart failure. - Interstitial lung disease: dyspnea and cough with infiltrates on imaging.

Before initiating therapy, clinicians should assess baseline organ function and monitor patients regularly.

- Monitor liver function: obtain baseline and periodic LFTs during treatment. - Assess cardiac status: perform baseline echocardiogram and repeat as indicated. - Check for skin reactions: report severe or worsening rash promptly. - Avoid in patients with known hypersensitivity to lapatinib or its excipients. - Store at ambient temperature: keep in the original pack, protect from moisture.

Lapatinib interacts with several drug classes that can alter its exposure or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce lapatinib levels. - QT‑prolonging agents (e.g., sotalol, quinidine): increase risk of cardiac arrhythmias. - Antacids containing aluminum or magnesium: can decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise lapatinib concentrations. - Warfarin: potential for altered INR, requiring closer coagulation monitoring. - Hormonal contraceptives: reduced efficacy, consider alternative non‑hormonal methods.